

# 1 Risk factor analysis of equine strongyle resistance to anthelmintics

2

3 Sallé G.<sup>1,\*</sup>, Cortet J.<sup>1</sup>, Bois I.<sup>2</sup>, Dubès C.<sup>2</sup>, Guyot-Sionest Q.<sup>3</sup>, Larrieu C.<sup>3</sup>, Landrin V.<sup>4</sup>,  
4 Majorel G.<sup>5</sup>, Wittreck S.<sup>6</sup>, Woringer E.<sup>7</sup>, Couroucé A.<sup>3</sup>, Guillot J.<sup>4</sup>, Jacquet P.<sup>2</sup>, Guégnard  
5 F.<sup>1</sup>, Blanchard A.<sup>1</sup>, Leblond A.<sup>5</sup>

6

7 <sup>1</sup>, INRA/Université de Tours UMR1282 Infectiologie et Santé Publique

8 <sup>2</sup>, UMR INRA/ENV Toulouse 1225 IHAP, Ecole Nationale Vétérinaire de Toulouse, France

9 <sup>3</sup>, LUNAM University, Oniris, unité de recherche NP3, 102 Route de Gachet, 44300 Nantes,  
10 France

11 <sup>4</sup>, Parasitology dept, Dynamyc EnvA, UPEC, Ecole nationale vétérinaire d'Alfort, UPE,  
12 Maisons-Alfort, France

13 <sup>5</sup>, EPIA, INRA, VetAgroSup, University of Lyon, 69280 Marcy L'Etoile, France

14 <sup>6</sup>, Merial SAS, 29 avenue Tony Garnier, 69007 Lyon, France

15

16 <sup>7</sup>, Zoetis, 10 rue Raymond David, 92240 Malakoff, France

17

18 \*, corresponding author: [Guillaume.Salle@inra.fr](mailto:Guillaume.Salle@inra.fr)

19 Permanent address : INRA Val de Loire, F-37380 Nouzilly, France

20

21

## 22    **Abstract**

23    Intestinal strongyles are the most problematic endoparasites of equids as a result of their wide  
 24    distribution and the spread of resistant isolates throughout the world. While abundant  
 25    literature can be found on the extent of anthelmintic resistance across continents, empirical  
 26    knowledge about associated risk factors is missing. This study brought together results from  
 27    anthelmintic efficacy testing and risk factor analysis to provide evidence-based guidelines in  
 28    the field. It involved 688 horses from 39 French horse farms and riding schools to both  
 29    estimate Faecal Egg Count Reduction (FECR) after anthelmintic treatment and to interview  
 30    farm and riding school managers about their practices. Risk factors associated with reduced  
 31    anthelmintic efficacy in equine strongyles were estimated across drugs using a marginal  
 32    modelling approach. Results demonstrated ivermectin efficacy (96.3% FECR), the inefficacy  
 33    of fenbendazole (42.8% FECR) and an intermediate profile for pyrantel (90.3% FECR). Risk  
 34    factor analysis provided support to advocate for FEC-based treatment regimens combined  
 35    with individual anthelmintic dosage and the enforcement of tighter biosecurity around horse  
 36    introduction that contributed to lower drug resistance risk by 1.75. Premises falling under this  
 37    typology also relied more on their veterinarians suggesting they play an important role in the  
 38    sustainability of anthelmintic usage. Similarly, drug resistance risk was halved in premises  
 39    with frequent pasture rotation and with stocking rate below five horses/ha. This is the first  
 40    empirical risk factor analysis for anthelmintic resistance in equids, whose findings should  
 41    guide the implementation of more sustained strongyle management in the field.

42

43    **Keywords:** horse, nematode, anthelmintic resistance, strongyle, cyathostomin

44

## 45 1. Introduction

46 The diversity of helminth species infecting horses is large, and differences in life cycles,  
 47 epidemiology, pathogenicity and drug susceptibility make it increasingly challenging to  
 48 define good sustainable parasite control programs. Strongyles remain a major concern. They  
 49 can be classified into two sub-families, namely Strongylinae (large strongyles) and  
 50 Cyathostominae known as small strongyles or cyathostomins (Lichtenfels et al., 2008). The  
 51 large strongyle *Strongylus vulgaris* is associated with a high mortality rate resulting from  
 52 parasite associated verminous arteritis (Nielsen et al., 2016). This species has been  
 53 successfully controlled by anthelmintics, despite recent reports of putative re-emergence  
 54 associated with reduced frequency of anthelmintic treatments (Nielsen et al., 2012; Nielsen et  
 55 al., 2016). On the contrary, cyathostomins have become a growing concern in the field  
 56 (Matthews, 2014; Peregrine et al., 2014). This group of nematodes encompasses 50 known  
 57 species (Lichtenfels et al., 2008) that infect both young and adult horses (Corning, 2009) and  
 58 have a ubiquitous distribution throughout geo-climatic conditions (Sallé and Cabaret, 2015a).  
 59 Their life cycle is direct and usually involves encystment of infective larvae into the caeco-  
 60 colic mucosa of their hosts (Corning, 2009). In heavily infected horses, *en-mass* emergence  
 61 of these encysted larvae can cause severe clinical pathology characterized by a loss of weight,  
 62 colic, diarrhoea, protein-losing enteropathy and the eventually death of the animal (Murphy  
 63 and Love, 1997; Love et al., 1999).

64 The use of anti-infectious drugs puts pathogen populations under selection pressure that can  
 65 ultimately lead to the emergence of resistant or multi-drug resistant populations (Kennedy  
 66 and Read, 2017). Over the past decades, small strongyle populations, like other livestock-  
 67 infecting parasitic nematodes (Kaplan and Vidyashankar, 2012), have demonstrated a gradual  
 68 increase in their resistance to available anthelmintics in every part of the world (Matthews,  
 69 2014; Peregrine et al., 2014). Under French settings (Traversa et al., 2012) like in other

European (Traversa et al., 2007; Traversa et al., 2009; Relf et al., 2014) or American countries (Slocombe and de Gannes, 2006; Lyons et al., 2008; Molento et al., 2008; Canever et al., 2013), resistant strongyle populations have been reported for every available class of anthelmintics, namely benzimidazoles, tetrahydropyrimidines or macrocyclic lactones. Although previous studies have demonstrated how widespread anthelmintics resistance is, critical assessment of associated risk factors and species composition of resistant parasitic populations is still lacking (Nielsen, 2012), thereby preventing the implementation of clear field guidelines. There have been a limited number of reports focusing on factors associated with prevalence of strongyle infection in horses in Germany (Fritzen et al., 2010; Hinney et al., 2011a) or the impact of faeces removal on prevalence in the UK (Corbett et al., 2014). Available studies have considered drenching practices (Lendal et al., 1998; O'Meara and Mulcahy, 2002; Lind et al., 2007; Hinney et al., 2011b; Relf et al., 2012) or estimation of anthelmintic efficacy (Relf et al., 2014; Tzelos et al., 2017). But no attempt has been made to reconcile drenching practices and drug efficacy data. As a consequence, a knowledge gap about putative risk factors and their impacts remains (Nielsen, 2012).

The results reported herein have been gathered as part of a large-scale survey involving 688 horses from 39 French horse farms and riding schools. At each location, an anthelmintic efficacy test and a questionnaire interview about their practices were performed. From this data, risk factors associated with reduced anthelmintic efficacy in equine strongyles have been estimated across drugs. The objective of this study was to bring together anthelmintic efficacy testing and risk factor analysis to provide evidence-based guidelines to the field.

## 93 2. Materials and methods

### 94 2.1. Farm and riding school sampling

95 Our study aimed to evaluate drug efficacy for three drug classes and if possible, to have a  
 96 control group. Therefore, we aimed to build four groups of at least five horses with a minimal  
 97 faecal egg count (**FEC**) of 150 eggs/g as recommended by the World Association for the  
 98 Advancement of Veterinary Parasitology, WAAVP guidelines (Coles et al., 1992). To reach  
 99 this number of infected individuals, bigger stud farms, i.e. with at least 20 producing mares,  
 100 were pre-selected from the French Horse and Riding Institute (IFCE) database, in Normandy,  
 101 Loire Valley, Aquitaine and Burgundy.

102 Two additional criteria were defined to increase the chance of finding horses with sufficient  
 103 excretion load to undertake FEC reduction test. First, premises with less than 40 horses were  
 104 discarded as FEC is usually over-dispersed and focusing on fewer individuals would have  
 105 reduced our chance to build treatment groups. In Aquitaine however, two farms with slightly  
 106 smaller herd sizes (25 and 31 horses) were enrolled. Second, last anthelmintic treatment  
 107 should have been performed three months earlier as this corresponds to the minimal post-  
 108 moxidectin treatment egg reappearance period (Boersema et al., 1998) advertised on product  
 109 information (Tzelos et al., 2017). Flyers explaining the purpose of the project were then sent  
 110 to pre-selected farms before a phone call was made to each manager to make sure that their  
 111 premises fulfilled requested criteria (at least 40 horses not drenched in the last three months)  
 112 and to confirm their willingness to participate. Nineteen stud farms were enrolled, *i.e.* five in  
 113 Normandy, four in Loire Valley, four in Burgundy and six in Aquitaine. Approximately half  
 114 of these farms (n=11) were involved in horse racing (Thoroughbreds and Anglo-Arabians,  
 115 French trotters or Thoroughbreds and other than Thoroughbreds), while the remainder  
 116 produced leisure ponies (n=4) or leisure horses (n=3) or reared dairy mares (n=2). For each of  
 117 these, matching riding schools located within each stud farm area were subsequently

identified and enrolled for anthelmintic efficacy test, with an additional riding school enrolled in Aquitaine, providing a set of 20 riding schools. This set of matched riding schools was used to investigate putative differences between stud farms and riding schools.

## **2.2. Horse sampling and anthelmintic resistance tests**

A first round of faecal sampling was made one week before drenching, to select for individuals with a minimum excretion level of 150 eggs per g (epg) as recommended by the WAAVP guidelines (Coles et al., 1992). Faecal material was stored at 4°C before being processed for faecal egg counting within 24h. Based on individual FEC measured, three treatment groups, *i.e.* fenbendazole (Panacur Equine Guard<sup>®</sup>, Intervet, France), pyrantel (Strongid<sup>®</sup>, Zoetis, France), or ivermectin (Eqvalan pâte, Merial, France), balanced for FEC were built. To do so, individuals were sorted according to their FEC and sequentially allocated to each treatment group. A control group was built in every farm where additional horses with minimal excretion level were available. On day 0, each horse was weighed using a girth tape and orally administered an anthelmintic dose following manufacturer's requirements. Treatment was administered by the veterinarians enrolled as part of this project.

Faecal material was subsequently taken from each horse 14 days after treatment. Every ivermectin-treated individual still present on the premise 30 days after drenching (n=157 out of 159) was sampled again to identify cases of shortened egg-reappearance period. This short time interval was chosen to minimise disturbance with activities on the premises (horse sales or movements).

## **2.3. Processing of faecal material**

FEC were measured by sampling 5g of faecal material for each individual horse, subsequently diluted and thoroughly mixed into 75 mL of a NaCl solution (density of 1.18). Prepared solution was loaded on a McMaster slide and strongyle eggs were counted with a sensitivity of 15 epg.

## **2.4. Questionnaire survey and variable definition**

A questionnaire, built upon previous published surveys (Fritzen et al., 2010; Maddox et al., 2012), was used to interview each manager as part of a larger survey on antibiotic and anthelmintic resistance. The anthelmintic-associated questions fell into four categories that addressed global premise overview, available pasture and management, horse health management, and drenching strategy.

For statistical inference, a few variable levels were redefined to avoid redundancy and to provide the analysis with more statistical power. Therefore, one farm that did not apply systematic drenching upon horse arrival was considered as not drenching any horse upon arrival. Rotation between pastures was recoded as occurring either never, or more (frequent) or less (rare) than every 3 months.

In addition, pasture strategies either involved own private pastures dedicated to horses or alternative strategies that included co- grazing with cattle, or access to pastures shared between several breeders. Stocking density was also computed as the herd size divided by available pasture surface, and binned into three categories (more than 5 horses/ha, between 2 to 5 horses/ha or less than 1 horse/ha). A three-level workload variable was defined as the number of horses per worker, falling in either less than 10 horses/employee, between 10 and 20 horses/employee or more than 20 horses/employee.

Two types of managers were defined; those who tried to manage health problems themselves before calling their practitioner and those who called as soon as possible.

Anthelmintic provider was considered as a two-level factor contrasting cases where veterinarians delivered the drug or not. The reasons guiding drenching programs were the same across farms, *i.e.* driven by horse well-being and growth, and were not included further in the risk factor analysis. In the end a set of 21 variables was used (supplementary table 1).

## 2.5. Statistical analyses

### 2.5.1. Egg Reduction Rate (FECR) and bootstrapping procedure

Sample size to estimate reduced FECR prevalence was determined using EpiTools web-server (Humphry et al., 2004).

When a control group was available, FECR values was computed at farm level by averaging treatment group FEC following (Dash et al., 1988):

$$ERR = 1 - \left( \frac{\text{mean FEC control, before treatment}}{\text{mean FEC control, after treatment}} \times \frac{\text{mean FEC treated, after treatment}}{\text{mean FEC treated, before treatment}} \right) \times 100,$$

hereafter referred to as **Method 1**.

Otherwise, FECR has been computed following (Coles et al., 1992):

$$ERR = \left( 1 - \frac{\text{mean FEC treated, after treatment}}{\text{mean FEC treated, before treatment}} \right) \times 100,$$

hereafter denoted **Method 2**.

Drug class FECR confidence intervals at the farm level were not estimated as too few individuals were available within each treatment group preventing robust inference of estimate variability (Chernick, 1999). However, for both methods, associated 95% percentile confidence intervals was determined for the region, premise type and drug class and their respective intersections following a block bootstrap approach. This approach takes into account the correlation among observations from the same individual (before and after treatment). For both FECR computation methods, blocks of FECs from the same horse were sampled with replacement from the observed data collected before and after treatment (within region, premise type and drug class), and were used to compute an FECR estimate using



equation (1) or (2) accordingly. In that case of method 1, the time-matched control group is used to account for variation in FEC between the two sampling time-points independent of treatment. Therefore, blocks of individual FEC before and after treatment were sampled with replacement from horses belonging to the treated or the control group within a farm. In both cases, computation was performed 10,000 times to yield the empirical distribution of the FECR from which 2.5 and 97.5% percentiles were sampled to derive the 95% confidence interval.

Pearson's correlations between FECR of the two methods were estimated using observations from the 24 premises where a control group was available using the *rcorr()* function of the Hmisc package v4.0-3 (Harrell and Dupont, 2017).

## 2.5.2. Variable selection procedure

To overcome model convergence issues, variables showing too little or no variation across sites (control serology or coproscopy upon horse arrival, faeces removal, access to pasture, horse weight estimation, veterinarian specialization, number of veterinary practices considered for diagnostic) were discarded. Additionally, the total number of veterinary drugs found on-site or the frequency of health register updates were not considered further as determinants of anthelmintic efficacy.

The aim of this study was to quantify risk factors associated with reduced anthelmintic efficacy, hence associating measured drug efficacy with management practices. This requires the selection of variables that would maximize the total variance explained, while avoiding biased estimates through collinearity (Zuur et al., 2010).

Pair-wise Pearson's correlations between variables were estimated to identify collinearity and avoid redundancy in subsequent modelling of anthelmintic efficacy (supplementary data 2). Any correlation coefficient equal to or above 0.4 was considered as indicative of collinearity.

As a result, veterinary advice, health management and the off-licence use of anthelmintics that were accounted for by other variables, were not considered any further.

### **2.5.3. Dimensionality reduction by Multiple Correspondance Analysis (MCA)**

While the discarding of strongly correlated variables addressed the most problematic collinear relationships, significant correlations were still present between the 18 remaining variables (supplementary data 2).

Remaining variables were related to the use of anthelmintics, the use of pasture, or the general constraints applying to the premise (work load measured by the number of horses per employee, and annual veterinary expenses per horse). For each of these three categories, a multiple correspondence analysis was performed on the dedicated set of variables with the FactoMineR v.136 package (Lê et al., 2008). Premise coordinates on the first two components of the MCA were subsequently used to define three-level (premise constraints variable) or four-level variables (anthelmintics and pasture usage).

### **2.5.4. Marginal modelling of drug efficacy**

A marginal modelling approach of individual horse egg count reduction rate (FECR) was applied as outlined elsewhere (Walker et al., 2014) and implemented in R (R Core Team, 2016) with the geepack package v1.2-1 (Højsgaard S., 2006). In that framework, individual egg counts measured at a given time, before or after treatment, are assumed to be Poisson distributed and thus modelled with a log-linear regression model.

This model includes environmental variables (premise type, region, and the three variables built from the MCA) interacting with a binary variable coding for the treatment, *i.e.* taking value of 1 after treatment or 0 before treatment. This variable accounts for the treatment-mediated change in egg count reduction, hence estimating FECRs, while the fitted

interactions estimate the contribution of considered environmental conditions to FECRs (Crellen et al., 2016). Exponentiated estimates therefore provide the relative risk of increased (relative risk above one) / decreased (relative risk smaller than one) FECRs associated with a given environmental variable. Any variable whose relative risk confidence interval does not include one is declared as significantly impacting on the FECRs. A forward-backward procedure was implemented with the *stepAIC()* function of the R MASS package v7.3-47 to select for the model minimizing the Akaike Information Criterion.

The model aimed to quantify universal risk factors, *i.e.* considered environmental effects across drug class. Treatment group was thus added into the model. Drug class-specific analyses based on individual treatment group data taken separately did not provide reliable results and were not reported.

## 3. Results

### 3.1. Observations from questionnaire surveys

Detailed answers from questionnaire surveys are provided as supplementary data 1.

#### 3.1.1. Overview of the enrolled premises

At least three treatment groups could be built in every location. However, herd size was highly variable between sites, ranging from 21 to 250 individuals (mean herd size of 70 horses). This variation was mostly driven by the herd being bigger in stud farms than in riding schools (average herd size of 88.3 and 52.2 respectively;  $p=0.008$ ). Horses were generally housed in individual boxes ( $n=31/39$ ) and a few premises had an outdoor-only breeding system ( $n=7/39$ ). Noticeably, staff size did not strongly correlate with herd size ( $r=0.33$ ,  $p=0.04$ ), especially in stud farms where workers were in charge of 13 horses more than in riding schools ( $p<10^{-4}$ ).

#### 3.1.2. Horse movements on site

Horse movement occurred in half of the premises ( $n=21/39$ ) at least once a month while seven premises were rarely housing horses from other places. For these introductions, no serology, no coproscopy and no anthelmintic efficacy tests were performed in any of the 39 premises, whereas anthelmintic drenching upon arrival was implemented in 11 riding schools and seven stud farms. Only four managers reported seeking advice from their veterinarians to manage these movements.

#### 3.1.3. Pasture availability and management

In every site, horses had outdoor access and could generally grazed throughout the year ( $n=27/39$ ). Most premises had their own pastures that were grazed by horses only. Three

farms had access to pastures shared with other breeders, and mixed grazing of horses with cattle was implemented in seven premises. Stocking density was below 3 horses/ha in 75% of sites. However, it was as high as 14 horses/ha and was generally higher in riding schools than in stud farms (average densities of 1.3 and 4.3 horses/ha respectively,  $p=2 \times 10^{-4}$ ). Rotation between pastures was implemented in 29 locations at least once a year and driven by grass growth. Faeces removal was implemented in one premise. Manure spreading was performed in one third ( $n=10/39$ ) of the surveyed sites.

### **3.1.4. Health management and interactions with veterinarians**

About two-thirds of the premises relied on specialized equine practitioners ( $n=24/39$ ), who were often called after managers had already attempted to manage health problem themselves ( $n=28/39$ ). Half of the premises ( $n=20/39$ ) were consulting several practices to cross-validate advice, or benefit from several skills, or both.

Yearly veterinary expenses per horse varied from less than 100 € ( $n=15$ ), between 100 and 200 € ( $n=14$ ), or more than 200 € ( $n=10$ ).

Importantly, managers reporting to be more independent in health management were over-represented in sites not implementing any measure upon horse introduction (13/39) and in the sites spending less than 100€/horse/year ( $r=-0.39$  and  $-0.41$  respectively; supplementary table 1). Health management was hence confounded by the two other variables and not considered further.

Mandatory on-site health register was variably used, *i.e.* 20 managers fulfilled it regularly (systematically or on a regular basis), while 19 rarely did it (never or doing it from time to time). The number of veterinary drugs found within on-site pharmacy greatly varied from null to 15, with two-thirds of premises having 5 drugs or less with a slight trend of more medications found in horse riding schools (Kruskal-Wallis test,  $p=0.07$ ).

303

### 304 **3.1.5. Drenching strategy for intestinal nematodes**

305 Anthelmintic dosing was usually based on a visual weight estimate (n=27/39) that could be  
 306 combined with girth tape (n=9/39), and rarely with a scale (n=2/39). Grouped-based  
 307 drenching was carried out in 11 sites. Time of drenching was registered most of the time  
 308 (n=31). Drenching frequency occurred two (n=13), three (n=11) or four times (n=14) a year,  
 309 and drenching programs alternated between drug classes.

310 Noticeably, a limited fraction of premises (n=6) reported off-license use of anthelmintics  
 311 despite most of the managers seeking advice from their veterinarians (5 out of 6). These  
 312 involved ivermectin (n=3), doramectin (n=2) or praziquantel (n=2) licensed for ruminants.  
 313 The off-licence use of anthelmintics was only reported in premises implementing two (n=5)  
 314 or three (n=1) annual treatments, resulting in a negative correlation between these two  
 315 variables ( $r=-0.41$ , supplementary data 2). The off-licence variable was hence not considered  
 316 further in the modelling analysis.

317 Anthelmintics were bought from veterinarians in 62% of cases, while three and 16 managers  
 318 reported buying from the internet or their pharmacist, respectively. In the latter case, only  
 319 three managers were aware of the legal requirement of showing a veterinarian's prescription  
 320 to the pharmacist.

321 The delivery of anthelmintics by veterinarians occurred more frequently when they  
 322 contributed to the drenching scheme design, *i.e.* 79 % of cases against 40% when they did not  
 323 ( $r=0.4$ , supplementary table 2). In addition, stud farm managers relied more on their  
 324 veterinarian's advice for drenching in comparison to their riding school counterparts (84% of  
 325 stud farms vs. 67 % of riding schools;  $r=0.45$ , supplementary table 2). Premises that did not  
 326 rely on veterinary advice also did not implement any measure upon horse arrival ( $r=0.47$ ,

p=0.003; supplementary table 2). Veterinary advice was hence accounted for three other variables, and was not considered further in the analysis.

FEC-based drenching regimen was implemented in 14 premises.

### **3.2. Results of anthelmintic efficacy tests**

This design provided enough resolution to detect prevalence as low as 1%, with precision of 0.05 and assuming FEC sensitivity of 70% and specificity of 90%.

A total of 688 horses from 39 premises were sampled at least once during this experiment.

Out of these, 601 horses excreting more than 150 epg before treatment were enrolled for the anthelmintic resistance test (Table 1). Control groups were available in 24 out of the 39 retained farms (Table 1). Average FEC before treatment was  $912 \pm 762$  epg (supplementary data 3).

Estimated Faecal Egg Count Reduction (FECR) and associated variation have been reported in Table 1 while premise-level estimated FECR have been attached as supplementary data 4. FECRs measured in the 24 sites where control group was available showed highly consistent results between the two implemented calculation methods for ivermectin and fenbendazole (Pearson's correlation coefficient of 100 and 82%, respectively). This correlation however dropped to 65% for pyrantel.

Estimated FECRs demonstrated the almost generalized inefficacy of fenbendazole with an average FECR of 46.2% (sd=33.5%) or 42.8% (sd = 33.4%) for method 1 and 2, respectively and confidence intervals not including 100% efficacy in Burgundy and Aquitaine (Table 1, supplementary data 4). Nevertheless, two riding schools and one stud farm located in Normandy exhibited FECRs of at least 90% (supplementary data 4).

Observed trends for ivermectin were the exact opposite of these, as the mean estimated FECRs were 98.1% (sd: 8.6%) and 96.3% (sd: 14.5%) according to methods 1 and 2, respectively (Table 1, supplementary data 4). Seven horses from three riding schools and

three stud farms exhibited FECRs lower than 90% after ivermectin treatment, resulting in bigger confidence intervals in Aquitaine and Normandy (Table 1). Egg reappearance was investigated 30 days after ivermectin drenching, *i.e.* based on FEC from 157 available horses. At this time, only nine horses excreted strongyle eggs (mean FEC of 14.6 epg). These were found in eight farms (three from Burgundy, four from Aquitaine and one from Loire Valley) and one riding school from Aquitaine. Only three of these horses had egg excretion levels above 50% of their before treatment FEC.

Pyrantel exhibited an intermediate profile in comparison to the two other drugs as average FECRs were close to the 90% threshold, *i.e.* 92.5% (sd: 15.4%) and 90.3% (sd: 19.6%) for methods 1 and 2, respectively (Table 1).

### **3.3. Risk factors associated with anthelmintic efficacy**

The variation in FEC before and after treatment was explicitly modelled by considering every individual FEC and by correcting for the farm environmental variables. This is to better capture the inter-individual variations associated with FEC while estimating the relative risk associated with environmental variables. Relative risks associated with reduced FECR were estimated across drug categories, any relative risk above 1 indicating an increased egg count after treatment and thus reduced efficacy. Drug-specific risk factors were subsequently estimated considering observations from each treatment group independently.

#### **3.3.1. Multivariate analysis and summary variables**

An MCA was applied to the set of variables related to the use of pasture and anthelmintics (figure 1) or the constraints applying to the premise (figure 2) to avoid fitting collinear variables in the drug efficacy model.



The MCA applied to the variables related to pasture usage accounted for 42% of the between-variable variance (figure 1A) and distinguished between four contrasted typologies. The first typology regrouped premises where grazing options were limited, *i.e.* mostly indoor housing and seasonal grazing with rare rotation between pastures. While typologies 1 and 3 were mostly driven by the housing system, the split between the other two systems was accounted for by the pasture surface availability (figure 1A). The 2<sup>nd</sup> pasture usage typology clustered together premises with the lowest stocking density, that were also able to perform manure spreading and frequent rotation between pastures. These four typologies were used to build a pasture usage variable for subsequent modelling.

The same approach resolved 31% of the variation in anthelmintics usage between premises (figure 1B). In this case, typologies 2 and 4 distinguished between premises with the most extreme behaviors regarding drug use. Premises falling under typology 2 applying strategies usually regarded as the most sustainable for drug resistance and typology 1 represented an intermediate situation between typologies 2 and 4. Typology 3 grouped together premises relying on a single annual macrocyclic lactone treatment. These four typologies were used to build an anthelmintic usage variable for subsequent modelling.

The two remaining variables to be considered addressed the annual veterinary expenses and the workload in premises (figure 2). These two variable were summarized as a so-called “constraint” variable that distinguished between three situations. Typology 2 described the most heavily constrained premises with highest workload and veterinary expenses (figure 2), whereas typology1 and 3 accounted for the smallest workload and most reduced veterinary expenses respectively (figure 2). Typology 1, defined by more limited workload and intermediate veterinary expenses, mostly encompassed riding schools. However, the correlation between the premise type and the three constraint levels was not significant ( $r=0.26$ ,  $p=0.1$ , supplementary table 5).

No residual significant correlations existed between variables considered for modeling (supplementary table 5).

### 3.3.2. Risk-factors across anthelmintic drug class

Modeling of drug efficacy relied on a set of six variables, *i.e.* day of treatment, treatment group, region and the three summary variables derived from MCA.

A first analysis investigated universal factors associated with drug efficacy, measured by FECR, that would be true across anthelmintic drugs and would not depend on the drug mode of action. Relative risks associated with the retained variables have been provided in table 2. Noticeably, the interaction term between the day of treatment and premise type or the region of interest or premise constraints were not retained by the model selection procedure, suggesting these variables were not providing information to the modelling of drug efficacy that had not been already accounted for by other variables.

In line with estimated FECRs, pyrantel and ivermectin were less at risk of reduced FECRs than fenbendazole considered as the reference level (Table 2).

Premises falling under the second typology of pasture usage (figure 1A) demonstrated a significant reduction of drug resistance risk (OR=0.53, p=0.001) in comparisons to other modalities (Table 2). This typology equally matched riding schools (n=6) or stud farms (n=5) but was over-represented in Normandy (6/11). This certainly explains why the site location was not retained in the model selection procedure.

The second typology of anthelmintic usage (figure 1B), that regroup strategies usually thought of as more sustainable toward drug resistance, was significantly associated with a reduced risk of drug resistance (OR=0.57, p=0.02). No significant differences could be made between other typologies (Table 1).

## 4. Discussion

Current knowledge about anthelmintic resistance in equine strongyles is usually scattered across drug efficacy reports and questionnaire surveys about parasite management (Nielsen, 2012). This leaves a major knowledge gap in the critical assessment of factors underpinning anthelmintic resistance in equids. Our study aims to fill in this gap with the report of an association between anthelmintic FECRs and management practices in horses.

The drug efficacy landscape in the present study remained similar to what was reported in a previous study in France (Traversa et al., 2012) and what was described in other countries (Matthews, 2014). In summary, fenbendazole cannot be used for the management of small strongyles any more, in contrast to ivermectin whose efficacy remained above 95%. Pyrantel had an intermediate efficacy FECR pattern with a 90% reduction of egg-excreting animals.

However, two original findings tend to depart from this general pattern. First, the risk of fenbendazole resistance was significantly lowered in Normandy with a few premises (3/39) still harbouring fenbendazole-susceptible strongyle populations. This was in line with a previous study (1/18) conducted in France (Traversa et al., 2012). However, it was not possible to identify an obvious consistent factor that would explain this sustained fenbendazole efficacy. In-depth investigation of practices and analysis of parasitic community structure with a nemabiome approach (Avramenko et al., 2015) may help better understanding this feature and then confirming fenbendazole-susceptibility by interrogating beta-tubulin sequences and allelic frequencies (Lake et al., 2009). Second, our results showed that ivermectin efficacy may not be sustained at its current level in the near future as egg excretion already took place 30 days after treatment in a limited number of horses across all regions. In addition, larger FECR confidence intervals were encountered in Normandy and Aquitaine, suggestive of a higher variability in ivermectin efficacy. Original ERP was 9 weeks for ivermectin (Boersema et al., 1996) but indications of shortened ERP have been

found in Germany (von Samson-Himmelstjerna et al., 2007), the UK (Daniels and Proudman, 2016), Belgium, the Netherlands and Italy (Geurden et al., 2014) and had never been reported in France. In this study, the quantitative determination of ERP was not possible due to practical reasons. Instead we focused on the 30<sup>th</sup> day post ivermectin treatment to minimize interferences of our design with activities on premises and to ensure that most of the treated horses would still be available for sampling. Despite this, a few horses had already been sold or sent to other premises for training.

Beyond the crude estimation of drug efficacy, this study aimed to identify major determinants underpinning egg reduction rate, and to estimate their respective relative contributions to provide evidence-based recommendations in the field.

Pasture-related variables were significant contributors to the variation in drug efficacy measured by egg reduction rate. Noticeably, sites with typology 2, that had the lowest stocking density, were able to implement frequent pasture rotation and to perform manure spreading, had a significantly decreased risk of drug resistance. Stocking density has been advocated as a factor driving drug resistance even if it could not be associated with more elevated infection rate in a German epidemiological study (Fritzen et al., 2010). On the contrary, frequent pasture rotation is one of the evasion strategy recommended to minimize pasture contamination (Michel, 1985). Therefore, it is probable that the combination of both a reduced horse density with frequent rotation between pastures minimized the use of drugs in these sites. The effect of manure spreading in the context of drug resistance remains uncertain. It could simply correlate with the available grazing surface and mirror the stocking density but this correlation was not significant in this dataset ( $r=-0.28$ ,  $p=0.09$ ).

Interestingly, drug resistance was significantly reduced in sites implementing a combination of FEC-based drenching programs, determination of drug dosage on an individual basis and a high level of biosecurity, *i.e.* little horse movement combined with a quarantine and

drenching upon horse introduction. Evidence-based drenching and individual drug dosage have long been advocated for in ruminant and equine systems as a sustainable parasite management practices, as the former is thought to reduce selection pressure (Kenyon et al., 2009) and the latter is thought to prevent under dosing whose impact on drug resistance development relies on many parameters (Smith et al., 1999; Silvestre et al., 2001). Our findings thus provided evidence to promote their enforcement in the field.

Notably, the more sustainable anthelmintic usage typology (typology 2) also accounted for the delivery of anthelmintic treatment by veterinarians. Under French regulations, veterinary medications can be delivered by veterinarians or pharmacists upon display of a veterinary prescription (Anonymous, 2007). This regulation was generally applied across the considered study sites and well correlated with the involvement of veterinarians into the drenching scheme design. Recent study in the UK suggests that practitioners may provide useful advice on drug use (Easton et al., 2016) and thus reinforce their role in sustainable parasite control. Such partnerships between veterinarians and horse owners should thus be encouraged in France as 40% of the considered sites designed their own drenching scheme.

These first insights into determinants of drug efficacy only focused on environmental factors, putting aside intrinsic worm characteristics, like species composition, that should be investigated further. Recent advances in parasite metagenomics would help addressing this question.

## Conclusions

This study reports the first risk estimation analysis between management practices and drug efficacy in equine strongyles. While drug resistance prevalence remains in agreement with previous surveys from France and other countries, *i.e.* a generalized failure of fenbendazole, a decreasing efficacy of pyrantel and reasonably high efficacy of ivermectin despite evidence of reduced egg reappearance period. Most importantly, we have quantified the relative risks and benefits associated with equine farms management practices. These estimations provided support to advocate for FEC-based treatment regimens as well as individual determination of anthelmintic dosage. In addition, tight biosecurity enforced by reduced horse movements and a combinaison of anthelmintic treatment with quarantine upon horse introduction should be recommended. Anthelmintics delivery by veterinarians was also among beneficial factors relative to drug resistance. Also, sites with frequent pasture rotations and stocking rate below five horses/ha displayed a reduced risk of drug resistance.

**Figure 1. Multiple correspondence analysis of the variables related to pasture (A) and anthelmintics (B) uses**

The first two components of the analysis are plotted and distinguish between four different typologies annotated in black (e.g. pasture.use1). Environmental variables are represented by red triangles while dots represent corresponding premises, colored according to the typology they belong to. Ellipses represent the 95% credible interval associated with each typology.

**Figure 2. Multiple correspondence analysis of the variables related to structural constraints applying to premises**

The first two components of the analysis are plotted and distinguish between three different typologies annotated in black (e.g. Constraint.1). Levels corresponding to the considered workload and veterinary expenses variables are represented by red triangles while dots represent corresponding premises, colored according to the typology they belong to. Ellipses represent the 95% credible interval associated with each typology.

529 **Table 1. Average Egg Reduction Rate estimated across premise type and regions**

Region		Ivermectin			Pyrantel			Fenbendazole		
		RS*	SF*	Across region	RS	SF	Across region	RS	SF	Across region
Aquitaine	N	26	27	53	29	26	55	29	28	57
3 RS (14)	mean	100	99,9	99,9	75,3	86,7	81	18,8	63	40,9
3 SF (15)	sd	0	0,1	0,1	39,5	16,4	27,8	32,5	41,1	41,1
	CI	[100-100]	[91.8-100]	[97.6-100]	[39.4-100]	[41.3-100]	[0-100]	[0-87]	[0-98.9]	[0-98.3]
Burgundy	N	15	17	32	13	19	32	16	19	35
3 RS (11)	mean	99,8	89,5	93,9	99,2	96,3	97,6	31,2	55,9	45,3
4 SF (19)	sd	0,3	21,1	15,9	1,4	4,3	3,5	27,9	26	27,8
	CI	[99.4-100]	[0-100]	[0-100]	[100-100]	[83.6-100]	[51.4-100]	[0-77.5]	[0-96.9]	[0-97.1]
Loire Valley	N	18	16	34	19	15	34	19	13	32
3 RS (14)	mean	100	100	100	97,2	93,3	95,2	32,5	68,2	50,4
3 SF (14)	sd	0	0	0	2,6	9,3	6,5	29,6	9,6	27,8
	CI	[100-100]	[100-100]	[100-100]	[85.3-100]	[50-100]	[19.6-100]	[0-78.6]	[0-100]	[0-100]
Normandy	N	18	22	40	19	23	42	21	22	43
2 RS (10)	mean	99	99,9	99,5	90,8	99,3	95,9	45,9	50,8	48,9
3 SF (15)	sd	1,4	0,2	0,9	12,3	1	7,7	64,9	46,9	46,5
		[82.2-100]	[95-100]	[0-100]	[80.3-100]	[92.8-100]	[60.3-100]	[0-100]	[0-100]	[0-100]
Across	N	77	82	159	80	83	163	85	82	167
premise	mean	99,8	96,7	98,1	90,6	94,1	92,5	30,8	59,2	46,2
type	sd	0,6	11,7	8,6	20,8	9,3	15,4	32,5	29,6	33,5
	CI	[98.8-100]	[95.2-100]	[95-100]	[39.4-100]	[58.9-100]	[41.3-100]	[0-92.3]	[0-100]	[0-100]

530

531



532 **Table 1 continued**

Region			Ivermectin			Pyrantel			Fenbendazole		
			RS*	SF*	Across region	RS	SF	Across region	RS	SF	Across region
Method 2: FECRT = 100 x (1 - FEC14/FEC0)	Aquitaine	mean	100	98,7	99,4	93,8	73,4	84,4	13,9	51,6	31,3
	7 RS	sd	0	2,9	2	6,9	36,2	26,1	14,7	41,8	34,9
	6 SF	CI	[100-100]	[70.8-100]	[79.2-100]	[0-100]	[0-100]	[0-100]	[0-79.6]	[0-98.7]	[0-98.5]
	Burgundy	mean	99,6	88,1	93,8	98,9	95,6	97,3	22,3	42,5	32,4
	4 RS	sd	0,5	23,8	16,8	1,5	4,8	3,7	30,2	37	33,1
	4 SF	CI	[96.3-100]	[0-100]	[0-100]	[91.4-100]	[78.6-100]	[78.6-100]	[0-88.2]	[0-92.4]	[0-92.4]
	Loire Valley	mean	100	79,5	89,8	96,5	74,1	85,3	36,1	60,9	48,5
	4 RS	sd	0	41	29	2,4	33,8	25,2	15,2	15,5	19,4
	4 SF	CI	[100-100]	[0-100]	[0-100]	[87.7-100]	[26.7-100]	[26.7-100]	[0-78.6]	[0-100]	[0-100]
	Normandy	mean	99,4	99,9	99,6	97,5	95,5	96,5	83,4	39,7	61,6
	5 RS	sd	1,3	0,2	0,9	3,2	8,9	6,4	18,2	36,2	35,5
	5 SF	CI	[60-100]	[99.2-100]	[99.2-100]	[85.1-100]	[38.7-100]	[85.1-100]	[0-100]	[0-100]	[0-100]
	Across premise	mean	99,8	92,7	96,3	96,3	84	90,3	37,4	48,5	42,8
		sd	0,7	21,1	15	4,8	26,5	19,6	33,6	33,3	33,5
	type	CI	[96.3-100]	[0-100]	[79.2-100]	[52.6-100]	[38.7-100]	[39.7-100]	[0-100]	[0-100]	[0-100]

533

534 Drug-specific average Egg Reduction Rates (mean) and standard deviations (sd) measured 14 days after treatment have been collated for each  
535 drug and region of interest for the two egg reduction rate calculation methods used. CI stands for Cross-sectional confidence intervals. N  
536 indicates the number of horses available, while RS and SF stand for riding-school and stud farm respectively. Figures in brackets under the  
537 Region column stands for the number of horses allocated to the control group in Riding Schools or Stud Farms accordingly.

**Table 2. Estimated odd ratios associated with retained environmental variables**

For each of the retained management practice, the relative risk of reduced (below 1) or increased (higher than 1) risk of anthelmintic resistance is provided. Associated 95% confidence intervals lower and upper limits are given as well as the associated *p* value.

<b>Variable</b>	<b>Odd ratio</b>	<b>Lower Odd Ratio</b>	<b>Upper Odd Ratio</b>	<b><i>p</i></b>
Ivermectin vs. Fenbendazole	0,02	0,01	0,08	<10 <sup>-2</sup>
Pyrantel vs. Fenbendazole	0,14	0,08	0,22	<10 <sup>-2</sup>
Pasture.use2 vs Pasture.use1	0,53	0,36	0,79	<10 <sup>-2</sup>
Pasture.use3 vs Pasture.use1	0,78	0,52	1,18	0,24
Pasture.use4 vs Pasture.use1	0,78	0,55	1,11	0,17
AH.use2 vs AH.use1	0,57	0,36	0,92	0,02
AH.use3 vs AH.use1	0,89	0,62	1,27	0,52
AH.use4 vs AH.use1	1,10	0,78	1,57	0,58

- 546     **Supplementary Data 1. Retained variables and data distribution across premises**
- 547     **Supplementary Data 2. Pair-wise Pearson's correlations between variables**
- 548     **Supplementary Data 3. Average faecal egg count by premise type and region before**
- 549     **anthelmintic treatment**
- 550     **Supplementary Data 4. Farm-level egg reduction rates with associated confidence**
- 551     **intervals**
- 552     **Supplementary Data 5. Correlation between variables retained for the modelling of**
- 553     **Faecal Egg Count Reduction**

## Acknowledgements

Authors are greatly indebted to the premise managers who took part to this study and gave us access to their stud or riding schools. We would like to acknowledge Pr. C. Chartier for kindly granting access to his parasitology laboratory, Dr. C. Laugier for discussing the questionnaire and Dr. L. Crespin for critical comments on this manuscript. We also would like to acknowledge the technical support of Dr. C. Charvet, C. Koch and C. Musset during this survey, and J. Noonan, A. Tracey and P. Driguez for their review of the English language. This work has been funded by the French Institute for Horse and Horse Riding (IFCE) and the Fonds Eperon fund for horse racing (BIOREQUI project), as well as the Merial and Zoetis companies.

## 566     **References**

- 567     Anonymous, 2007. Code de la Santé Publique - Article R5141-112, in: Française, R. (Ed.).  
568     Avramenko, R.W., Redman, E.M., Lewis, R., Yazwinski, T.A., Wasmuth, J.D., Gilleard, J.S.,  
569     2015. Exploring the Gastrointestinal "Nemabiome": Deep Amplicon Sequencing to Quantify  
570     the Species Composition of Parasitic Nematode Communities. *PLoS One* 10, e0143559.  
571     Boersema, J.H., Eysker, M., Maas, J., vanderAar, W.M., 1996. Comparison of the  
572     reappearance of strongyle eggs in foals, yearlings, and adult horses after treatment with  
573     ivermectin or pyrantel. *Vet Quart* 18, 7-9.  
574     Boersema, J.H., Eysker, M., van der Aar, W.M., 1998. The reappearance of strongyle eggs in  
575     the faeces of horses after treatment with moxidectin. *Vet Q* 20, 15-17.  
576     Canever, R.J., Braga, P.R., Boeckh, A., Grycajuck, M., Bier, D., Molento, M.B., 2013. Lack of  
577     *Cyathostomin* sp. reduction after anthelmintic treatment in horses in Brazil. *Vet Parasitol*  
578     194, 35-39.  
579     Chernick, M.R., 1999. Bootstrap Methods: A practitioner's guide.  
580     Coles, G.C., Bauer, C., Borgsteede, F.H., Geerts, S., Klei, T.R., Taylor, M.A., Waller, P.J., 1992.  
581     World Association for the Advancement of Veterinary Parasitology (W.A.A.V.P.) methods for  
582     the detection of anthelmintic resistance in nematodes of veterinary importance. *Vet*  
583     *Parasitol* 44, 35-44.  
584     Corbett, C.J., Love, S., Moore, A., Burden, F.A., Matthews, J.B., Denwood, M.J., 2014. The  
585     effectiveness of faecal removal methods of pasture management to control the  
586     *cyathostomin* burden of donkeys. *Parasit Vectors* 7, 48.  
587     Corning, S., 2009. Equine *cyathostomins*: a review of biology, clinical significance and  
588     therapy. *Parasit Vectors* 2 Suppl 2, S1.  
589     Crellen, T., Walker, M., Lamberton, P.H., Kabatereine, N.B., Tukahebwa, E.M., Cotton, J.A.,  
590     Webster, J.P., 2016. Reduced Efficacy of Praziquantel Against *Schistosoma mansoni* Is  
591     Associated With Multiple Rounds of Mass Drug Administration. *Clin Infect Dis* 63, 1151-  
592     1159.  
593     Daniels, S.P., Proudman, C.J., 2016. Shortened egg reappearance after ivermectin or  
594     moxidectin use in horses in the UK. *Vet J* 218, 36-39.  
595     Dash, K.M., Hall, E., Barger, I.A., 1988. The role of arithmetic and geometric mean worm egg  
596     counts in faecal egg count reduction tests and in monitoring strategic drenching programs in  
597     sheep. *Aust Vet J* 65, 66-68.  
598     Day, T., Read, A.F., 2016. Does High-Dose Antimicrobial Chemotherapy Prevent the  
599     Evolution of Resistance? *PLoS Comput Biol* 12, e1004689.  
600     Easton, S., Pinchbeck, G.L., Tzelos, T., Bartley, D.J., Hotchkiss, E., Hodgkinson, J.E., Matthews,  
601     J.B., 2016. Investigating interactions between UK horse owners and prescribers of  
602     anthelmintics. *Prev Vet Med* 135, 17-27.  
603     Fritzen, B., Rohn, K., Schnieder, T., von Samson-Himmelstjerna, G., 2010. Endoparasite  
604     control management on horse farms--lessons from worm prevalence and questionnaire  
605     data. *Equine Vet J* 42, 79-83.  
606     Geurden, T., van Doorn, D., Claerebout, E., Kooyman, F., De Keersmaecker, S., Vercruysse, J.,  
607     Besognet, B., Vanimisetti, B., di Regalbano, A.F., Beraldo, P., Di Cesare, A., Traversa, D.,  
608     2014. Decreased strongyle egg re-appearance period after treatment with ivermectin and  
609     moxidectin in horses in Belgium, Italy and The Netherlands. *Vet Parasitol* 204, 291-296.  
610     Harrell, F.E., Dupont, C., 2017. Hmisc: Harrell Miscellaneous.

611 Hinney, B., Wirtherle, N.C., Kyule, M., Miethe, N., Zessin, K.H., Clausen, P.H., 2011a.  
612 Prevalence of helminths in horses in the state of Brandenburg, Germany. *Parasitol Res* 108,  
613 1083-1091.

614 Hinney, B., Wirtherle, N.C., Kyule, M., Miethe, N., Zessin, K.H., Clausen, P.H., 2011b. A  
615 questionnaire survey on helminth control on horse farms in Brandenburg, Germany and the  
616 assessment of risks caused by different kinds of management. *Parasitol Res* 109, 1625-1635.

617 Højsgaard S., H., U., Yan, J., 2006. The R Package geepack for Generalized Estimating  
618 Equations. *Journal of Statistical Software* 15, 1-11.

619 Humphry, R.W., Cameron, A., Gunn, G.J., 2004. A practical approach to calculate sample size  
620 for herd prevalence surveys. *Prev Vet Med* 65, 173-188.

621 Kaplan, R.M., Vidyashankar, A.N., 2012. An inconvenient truth: Global worming and  
622 anthelmintic resistance. *Veterinary Parasitology* 186, 70-78.

623 Kennedy, D.A., Read, A.F., 2017. Why does drug resistance readily evolve but vaccine  
624 resistance does not? *Proc Biol Sci* 284.

625 Kenyon, F., Greer, A.W., Coles, G.C., Cringoli, G., Papadopoulos, E., Cabaret, J., Berrag, B.,  
626 Varady, M., Van Wyk, J.A., Thomas, E., Vercruysse, J., Jackson, F., 2009. The role of targeted  
627 selective treatments in the development of refugia-based approaches to the control of  
628 gastrointestinal nematodes of small ruminants. *Vet Parasitol* 164, 3-11.

629 Kotze, A.C., Hunt, P.W., Skuce, P., von Samson-Himmelstjerna, G., Martin, R.J., Sager, H.,  
630 Krucken, J., Hodgkinson, J., Lespine, A., Jex, A.R., Gilleard, J.S., Beech, R.N., Wolstenholme,  
631 A.J., Demeler, J., Robertson, A.P., Charvet, C.L., Neveu, C., Kaminsky, R., Rufener, L.,  
632 Alberich, M., Menez, C., Prichard, R.K., 2014. Recent advances in candidate-gene and whole-  
633 genome approaches to the discovery of anthelmintic resistance markers and the description  
634 of drug/receptor interactions. *Int J Parasitol Drugs Drug Resist* 4, 164-184.

635 Lake, S.L., Matthews, J.B., Kaplan, R.M., Hodgkinson, J.E., 2009. Determination of genomic  
636 DNA sequences for beta-tubulin isotype 1 from multiple species of cyathostomin and  
637 detection of resistance alleles in third-stage larvae from horses with naturally acquired  
638 infections. *Parasites & Vectors* 2.

639 Lê, S., Josse, J., Husson, F., 2008. FactoMineR: A Package for Multivariate Analysis. *Journal of*  
640 *Statistical Software* 25, 1-18.

641 Lendal, S., Larsen, M.M., Bjorn, H., Craven, J., Chriel, M., Olsen, S.N., 1998. A questionnaire  
642 survey on nematode control practices on horse farms in Denmark and the existence of risk  
643 factors for the development of anthelmintic resistance. *Vet Parasitol* 78, 49-63.

644 Lichtenfels, J.R., Kharchenko, V.A., Dvojnjos, G.M., 2008. Illustrated identification keys to  
645 strongylid parasites (Strongylidae: Nematoda) of horses, zebras and asses (Equidae). *Vet*  
646 *Parasitol* 156, 4-161.

647 Lind, E.O., Rautalinko, E., Uggla, A., Waller, P.J., Morrison, D.A., Hoglund, J., 2007. Parasite  
648 control practices on Swedish horse farms. *Acta Vet Scand* 49, 25.

649 Love, S., Murphy, D., Mellor, D., 1999. Pathogenicity of cyathostome infection. *Vet Parasitol*  
650 85, 113-121; discussion 121-112, 215-125.

651 Lyons, E.T., Tolliver, S.C., Ionita, M., Collins, S.S., 2008. Evaluation of parasitocidal activity of  
652 fenbendazole, ivermectin, oxbendazole, and pyrantel pamoate in horse foals with emphasis  
653 on ascarids (*Parascaris equorum*) in field studies on five farms in Central Kentucky in 2007.  
654 *Parasitol Res* 103, 287-291.

655 Maddox, T.W., Pinchbeck, G.L., Clegg, P.D., Wedley, A.L., Dawson, S., Williams, N.J., 2012.  
656 Cross-sectional study of antimicrobial-resistant bacteria in horses. Part 2: Risk factors for  
657 faecal carriage of antimicrobial-resistant *Escherichia coli* in horses. *Equine Vet J* 44, 297-303.

658 Martinez-Valladares, M., Famularo, M.R., Fernandez-Pato, N., Cordero-Perez, C., Castanon-  
659 Ordonez, L., Rojo-Vazquez, F.A., 2012. Characterization of a multidrug resistant *Teladorsagia*  
660 *circumcincta* isolate from Spain. *Parasitol Res* 110, 2083-2087.

661 Matthews, J.B., 2014. Anthelmintic resistance in equine nematodes. *Int J Parasitol Drugs*  
662 *Drug Resist* 4, 310-315.

663 Michel, J.F., 1985. Epidemiology and Control of Gastrointestinal Helminths in Domestic  
664 Animals, in: Bossche, H.V., Thienpont, D., Janssens, P.G. (Eds.), *Chemotherapy of*  
665 *Gastrointestinal Helminths*. Springer Berlin Heidelberg, Berlin, Heidelberg, pp. 67-123.

666 Molento, M.B., Antunes, J., Bentes, R.N., Coles, G.C., 2008. Anthelmintic resistant  
667 nematodes in Brazilian horses. *Vet Rec* 162, 384-385.

668 Murphy, D., Love, S., 1997. The pathogenic effects of experimental cyathostome infections  
669 in ponies. *Vet Parasitol* 70, 99-110.

670 Nielsen, M.K., 2012. Sustainable equine parasite control: perspectives and research needs.  
671 *Vet Parasitol* 185, 32-44.

672 Nielsen, M.K., Jacobsen, S., Olsen, S.N., Bousquet, E., Pihl, T., 2016. Nonstrangulating  
673 intestinal infarction associated with *Strongylus vulgaris* in referred Danish equine cases.  
674 *Equine Vet J* 48, 376-379.

675 Nielsen, M.K., Vidyashankar, A.N., Olsen, S.N., Monrad, J., Thamsborg, S.M., 2012.  
676 *Strongylus vulgaris* associated with usage of selective therapy on Danish horse farms-is it  
677 reemerging? *Vet Parasitol* 189, 260-266.

678 O'Meara, B., Mulcahy, G., 2002. A survey of helminth control practices in equine  
679 establishments in Ireland. *Vet Parasitol* 109, 101-110.

680 Peregrine, A.S., Molento, M.B., Kaplan, R.M., Nielsen, M.K., 2014. Anthelmintic resistance in  
681 important parasites of horses: does it really matter? *Vet Parasitol* 201, 1-8.

682 R Core Team, 2016. R: A Language and Environment for Statistical Computing. R Foundation  
683 for Statistical Computing, Vienna.

684 Relf, V.E., Lester, H.E., Morgan, E.R., Hodgkinson, J.E., Matthews, J.B., 2014. Anthelmintic  
685 efficacy on UK Thoroughbred stud farms. *Int J Parasitol* 44, 507-514.

686 Relf, V.E., Morgan, E.R., Hodgkinson, J.E., Matthews, J.B., 2012. A questionnaire study on  
687 parasite control practices on UK breeding Thoroughbred studs. *Equine Vet J* 44, 466-471.

688 Sallé, G., Cabaret, J., 2015a. Meta-analysis of cyathostomins community structure and  
689 diversity, International Conference of the World Association for the Advancement of  
690 Veterinary Parasitology, Liverpool, The United-Kingdom, p. 220.

691 Sallé, G., Cabaret, J., 2015b. A survey on parasite management by equine veterinarians  
692 highlights the need for a regulation change. *Vet Rec Open* 2, e000104.

693 Silvestre, A., Cabaret, J., Humbert, J.F., 2001. Effect of benzimidazole under-dosing on the  
694 resistant allele frequency in *Teladorsagia circumcincta* (Nematoda). *Parasitology* 123, 103-  
695 111.

696 Slocombe, J.O., de Gannes, R.V., 2006. Cyathostomes in horses in Canada resistant to  
697 pyrantel salts and effectively removed by moxidectin. *Vet Parasitol* 140, 181-184.


698 Smith, G., Grenfell, B.T., Isham, V., Cornell, S., 1999. Anthelmintic resistance revisited:  
699 under-dosing, chemoprophylactic strategies, and mating probabilities. *Int J Parasitol* 29, 77-  
700 91; discussion 93-74.

701 Traversa, D., Castagna, G., von Samson-Himmelstjerna, G., Meloni, S., Bartolini, R., Geurden,  
702 T., Pearce, M.C., Woringer, E., Besognet, B., Milillo, P., D'Espois, M., 2012. Efficacy of major  
703 anthelmintics against horse cyathostomins in France. *Vet Parasitol* 188, 294-300.

704 Traversa, D., Klei, T.R., Iorio, R., Paoletti, B., Lia, R.P., Otranto, D., Sparagano, O.A.,  
705 Giangaspero, A., 2007. Occurrence of anthelmintic resistant equine cyathostome  
706 populations in central and southern Italy. *Prev Vet Med* 82, 314-320.  
707 Traversa, D., von Samson-Himmelstjerna, G., Demeler, J., Milillo, P., Schurmann, S., Barnes,  
708 H., Otranto, D., Perrucci, S., di Regalbono, A.F., Beraldo, P., Boeckh, A., Cobb, R., 2009.  
709 Anthelmintic resistance in cyathostomin populations from horse yards in Italy, United  
710 Kingdom and Germany. *Parasit Vectors* 2 Suppl 2, S2.  
711 Tzelos, T., Barbeito, J.S., Nielsen, M.K., Morgan, E.R., Hodgkinson, J.E., Matthews, J.B., 2017.  
712 Strongyle egg reappearance period after moxidectin treatment and its relationship with  
713 management factors in UK equine populations. *Vet Parasitol* 237, 70-76.  
714 von Samson-Himmelstjerna, G., Fritzen, B., Demeler, J., Schurmann, S., Rohn, K., Schnieder,  
715 T., Epe, C., 2007. Cases of reduced cyathostomin egg-reappearance period and failure of  
716 *Parascaris equorum* egg count reduction following ivermectin treatment as well as survey  
717 on pyrantel efficacy on German horse farms. *Vet Parasitol* 144, 74-80.  
718 Walker, M., Churcher, T.S., Basanez, M.G., 2014. Models for measuring anthelmintic drug  
719 efficacy for parasitologists. *Trends Parasitol* 30, 528-537.  
720 Zuur, A.F., Ieno, E.N., Elphick, C.S., 2010. A protocol for data exploration to avoid common  
721 statistical problems. *Methods Ecol Evol* 1, 3-14.  
722



A



B

